New research from Ocular Technology Group and CooperVision is challenging a common approach to addressing presbyopia among eye care professionals. The study findings illustrate how patients fit with MyDay^® daily disposable multifocal contact lenses achieved better binocular visual acuity at all distances and significantly greater binocular summation compared to monovision.

Investigation on the Influence of Presbyopia Correction on Binocular Vision Status (Guillon M, et al) will be shared as a scientific poster during this week’s 2022 American Academy of Optometry annual meeting.*

The prospective, non-dispensing, randomized, crossover, double-masked study enrolled 21 habitual multifocal contact lens wearers, evenly split between emerging, established, and advanced presbyopes. Subjects were dispensed CooperVision MyDay^® multifocal contact lenses with the Binocular Progressive System^™ following the fitting guide and single vision contact lenses using the same material. This was followed by assessments for monocular and binocular through focus visual acuity, horizontal and vertical phorias and fixation disparity, and stereopsis.

Investigators determined that binocular vision status with MyDay^® multifocal was maintained when compared to spectacle correction and offered good visual acuity at distances ranging from 400 cm to 40 cm. In addition, overall through focus binocular summation (mean binocular summation for all distances) was significantly greater with MyDay^® multifocal than the monovision fits (p < 0.001). The interocular blur difference between monocular visual acuities in the dominant and non-dominant eyes with MyDay^® multifocal was significantly lower than across low, medium, and high add spectacle groups.

“This work provides compelling evidence for fitting MyDay^® multifocal contact lenses instead of using a monovision approach across all levels of presbyopia,” said Percy Lazon de la Jara, Director of Research Programs for CooperVision and a paper co-author. “It’s important to recognize that these observations are specific to MyDay^® multifocal. This is the first contact lens to employ the CooperVision^® Binocular Progressive System^™, a three-ADD method that uses different lens designs to optimize vision for every stage of presbyopia.”

MyDay^® multifocal allows the eyes to work in tandem, which gives a simple initial fit and an easy progression as the near requirement increases. Wearers embrace the lens from the start, with 92% of patients satisfied overall on the initial fitting.² That performance helps wearers get back on the go and spend more time on the things that matter most to them—and may give ECPs more time to fit more patients.

This study joins multiple company-led and funded scientific papers and posters that will be presented at the American Academy of Optometry meeting, which takes place from October 26-29 in San Diego, California.

 Click HERE for the full press release.

New research from CooperVision explores accommodative behavior and retinal defocus performance of MiSight^® 1 day contact lenses in eyes with higher levels of myopia. Findings demonstrated that the dual focus optical design was able to introduce myopic defocus at all viewing distances.

With newly expanded parameters (up to -7.00 in Canada and the United States), Eye Care Professionals can confidently treat more age-appropriate children impacted by the growing prevalence and severity of myopia.

Introduction of myopic retinal defocus in highly myopic eyes using a dual focus myopia control contact lens (Gantes et al.) and Accommodative behavior and retinal defocus in highly myopic eyes fit with a dual focus myopia control contact lens (Meyer et al.) are being presented at the 2022 American Academy of Optometry annual meeting this week.

These scientific works examine highly myopic eyes (–6.50 to –10.00D, mean ± SD: –8.00±1.02D) fit with single-vision and MiSight^® 1 day lenses, revealing that eyes accommodated similarly in both cases. Small accommodative leads at distance did not prevent +2.00D myopic defocus in the MiSight^® 1 day treatment optics from being imposed on the retina. Researchers also found that higher powers did not prevent the lens from reducing hyperopic retinal defocus across the central 40 degrees of the horizontal retina.

“CooperVision has invested decades into myopia research and development to provide evidence-based interventions for children with this disease,” said Paul Chamberlain, BSc (Hons), Senior Director of Research Programs, CooperVision. “Combining these latest findings with our extensive and rigorous body of existing work helps eye care professionals take on myopia with more confidence, reaching even more children around the world.”

Chamberlain will present MiSight^® 1 day myopia control therapy assessment in fast and slow progressors, a paper that describes the proportional treatment effect that allows faster-progressing children to receive the maximum myopia control benefit. The analysis is based on data gathered during years four through six of the international MiSight^® 1 day clinical trial, when study participants were aged 11 to 15 years old.

The Academy designated this work as one of the ten most newsworthy developments at the entire meeting. Chamberlain will preview the findings during the Academy’s global virtual press conference this evening.

Supporting CooperVision’s comprehensive myopia management portfolio, Efficacy of Fitting Ortho-K Contact Lenses Utilizing a Mobile Fitting Application (Voltz et al) demonstrates how lens parameters recommended by the Paragon CRT^® Lens Calculator are in close alignment with those determined diagnostically, helping to save chair time.

The company also funded Preliminary Modification and Adaptation of a Quality of Vision Questionnaire for Children (Postnikoff et al.), research surrounding the modernization of a quality of vision questionnaire to make it suitable for optical myopia control interventions with children.

These studies join multiple company-led and funded scientific papers and posters that will be presented at the American Academy of Optometry meeting, which takes place from October 26-29 in San Diego, California.

Click HERE for the full press release.